VolitionRX (VNRX) Investor presentation summary

Recent achievements and milestones

• Cat paper submission expected to unlock a $5 million milestone payment; manuscripts for feline lymphoma and other studies submitted for peer review.

• FujiFilm Vet Systems launched Nu.Q Vet on automated i10 platform, expanding into non-sepsis disease areas.

• Mayo Clinic publication in trauma and DETECSEPS sepsis program on track for first patient in Q3 2026.

• Certification completed at three French hospitals; reimbursement submissions in preparation.

Business model and commercialization strategy

• Asset-light, low-capex, low-opex model focused on commercial partnerships and out-licensing.

• Monetizes IP through upfront, milestone, and recurring revenue from licensing and sales of key components.

• R&D conducted with research partners; targets broad geographic reach and large installed base for partners.

• Multiple licensing deals targeted in human diagnostics for 2026.

Product portfolio and validation

• Nu.Q Vet available in US, Europe, and Asia; detects 76% of systemic cancers at 97% specificity, priced at $35/test to vets.

• Nu.Q Cancer addresses all five blood test applications in lung cancer, with reimbursement dossier in preparation and direct sales expected in France in 2H 2026.

• Capture-seq enables world-first isolation of pure tumor-derived DNA from blood, offering thousands of new biomarkers.

• Nu.Q NETs targets sepsis and other acute/chronic conditions, with first sales in EU and government-backed DETECSEPS program.